Syneos Health Announces Strategic Collaboration and Investment in Indegene Omnipresence and the Company’s Next-Generation CRM and Omnichannel Engagement SaaS PlatformHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Syneos Health Announces Strategic Collaboration and Investment in Indegene Omnipresence and the Company’s Next-Generation CRM and Omnichannel Engagement SaaS PlatformGlobeNewswireJanuary 9, 2020ReblogShareTweetShareOmnipresence Platform Provides Biopharmaceutical Companies Advanced Analytics, AI and Cloud Innovations Powered by MicrosoftMORRISVILLE, N.C., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Syneos Health® (SYNH), the only fully integrated biopharmaceutical solutions organization, announced a strategic collaboration and minority investment in Indegene Omnipresence and the company’s next-generation unified customer experience platform.The Omnipresence platform is the result of a strategic alliance with Indegene, a leading global healthcare tech firm, which brings together Microsoft Power Platform, Dynamics 365, Azure, Office 365 including Teams, LinkedIn and Microsoft AI into a unified customer experience management (CXM) platform verticalized for the healthcare industry. Omnipresence helps life sciences and healthcare organizations drive intelligent customer relationships and experiences.By activating healthcare professional (HCP) end-to-end experiences, and unifying CRM and omnichannel technology together with advanced analytics and AI capabilities, the modern platform improves upon traditional CRM or multichannel technologies that focus on singular and disparate engagements. Omnipresence can deliver holistic, insights-driven experiences better aligned with HCP needs and preferences to enable increased impact and satisfaction.“The biopharmaceutical industry is under growing pressure to deliver value-based customer experiences in a far more competitive marketplace. Omnipresence offers customers a bold new choice – an innovative  platform, underpinned by Microsoft technologies, to drive intelligent commercial relationships,” said Alistair Macdonald, Chief Executive Officer, Syneos Health. “The next-generation solution will enable customers to harness data to provide actionable insights and realize better commercial experiences, with improved return on investment.” “Omnipresence is a good example of an industry-specific, multi-cloud solution built with and on Microsoft’s enterprise technologies working together in uniquely disruptive ways. We are excited to see Indegene add Syneos Health as another strategic collaborator in our joint mission to bring new value to life sciences and healthcare organizations,” said James Phillips, Corporate Vice President, Business Applications Group, Microsoft.Omnipresence is the newest addition to Syneos Health’s Dynamic Assembly network, a broad and growing group of best-of-breed data and technology collaborators who enable Syneos Health to be data dynamic and ahead of the curve. Syneos Health curates an open ecosystem of the best, most agile data and technology partners to deliver fit-for-purpose solutions designed to strategically address the nuances of unique customer engagements. About Syneos HealthSyneos Health (SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life® visit syneoshealth.com.  Syneos Health Investor Relations Contact:Ronnie Speight   Senior Vice President, Investor Relations   +1 919 745 2745   Investor.Relations@syneoshealth.com      Syneos Health Press/Media Contact:Danielle DeForgeExecutive Director, External Communications+1 202 210 5992danielle.deforge@syneoshealth.com
ReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextTwo-time spaceflier Charles Simonyi offers advice for commercial space travelersGeekWire4 Giants See Stocks Plummet on Coronavirus WarningsGuruFocus.comPayPal Stock Falls On China Coronavirus Warning For Global E-CommerceInvestor's Business DailyBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance Video'Stuck in no man’s land': A working mom details dealing with her sick child's student loan billYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceWhat the GM strike means for the U.S. economyYahoo Finance